Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)

NCT06939283 is registered in ClinicalTrials.gov with Werewolf Therapeutics, Inc. as lead sponsor.

NCT NCT06939283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06939283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Werewolf Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 7, 2025
Completion date
August 31, 2028
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, non-hodgkin lymphoma